الفهرس 
Morbidity and mortality analysis of treatment with cytoreductive surgery and hyperthermic intrapoperative intraperitoneal chemotherapy national cancer institute experience
AbstractOnly 14 pages are availabe for public view
 |  | from | 100 |  |  |
| | | from | 100 | | |
Abstract
Objective: Peritoneal surface malignancy (PSM) is associated with death within a brief period of time. Since the 1990s, increasing evidence supporting the surgical management of PSM with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) has emerged, Therefore, we conducted the present retrospective study in order to evaluate the outcomes of CRS + HIPEC regimen in patients with intra-abdominal tumors. Methods: The present study included 63 patients with abdominal malignancies who were treated by CRS and HIPEC between January 2016 to December 2017 at the National Cancer Institue (NCI) of Cairo University. Results: The mean age of the included patients was 54.7 years old and almost half of the patients had more than 60 years old. The majority of patients were females (73%). In the present study, the most common cause of peritoneal surface malignancy was pseudeomyxoma peritonei (49.2%), followed by ovarian cancer (25.4%), ovarian adenocarcinoma (6.3%), and gastric cancer (3.2%). The 30-day postoperative mortality was 9.5%; while the overall mortality rate was 81%. In addition, the median time for overall survival was 12.007 months (95% CI 8 {u2013} 15.9 months). There were no significant associations between median survival and age, gender, diagnosis, preoperative chemotherapy, intraoperative, and postoperative complications. Regarding the disease-free survival (DFS) and recurrence, 7.9% of the patients had recurrent disease with a median DFS of 1.02 months (95% CI 0.36 {u2013} 1.7). Notably, patients with preoperative chemotherapy had significantly lower DFS